Description
Alecnib 150 MG (Alectinib) is an oral, second-generation, highly selective anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) supplied as a 150 mg tablet in a 56’s pack and manufactured by Everest Pharmaceuticals Ltd. for export. Its active ingredient, alectinib, potently inhibits the ALK kinase domain retaining full activity against the majority of crizotinib-resistant secondary ALK mutations including L1196M, G1269A, and I1171T while demonstrating exceptional central nervous system (CNS) penetration, achieving cerebrospinal fluid (CSF) concentrations that approximate estimated free plasma concentrations. This superior CNS bioavailability directly addresses brain metastasis progression, which occurs in up to 46% of patients on first-generation crizotinib therapy within the first two years of treatment. Alecnib 150 MG (Alectinib) is indicated for the first-line treatment of adults with ALK-positive advanced non-small cell lung cancer (NSCLC), for adults with ALK-positive advanced NSCLC previously treated with crizotinib, and since the landmark
April 2024 FDA approval for the adjuvant treatment of adults with completely resected stage IB (tumours ≥4 cm) to IIIA ALK-positive NSCLC. The definitive ALEX Phase III trial confirmed alectinib’s long-term superiority over crizotinib with a final median overall survival of 81.1 months versus 54.2 months (HR 0.78; 95% CI 0.56–1.08; data cutoff April 2025) and a final median progression-free survival of 34.8 months versus 10.9 months establishing alectinib as the global standard of care for ALK-positive advanced NSCLC. Searching for Alecnib 150 MG Alectinib? Mediaid Pharmacy lists this product within its comprehensive lung cancer medicines portfolio and ships it worldwide.
Basic Product Information of Alecnib 150 MG (Alectinib)
| Brand Name | Alecnib 150 MG (Alectinib) |
| Product Name | Alecnib |
| Generic Name | Alectinib INN |
| Drug Class | Second-Generation Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor (TKI); CNS-Active Targeted Thoracic Oncology Agent |
| Formulation | Tablet |
| Available Strength | 150 mg |
| Available Pack Size | 56’s (56 tablets per pack) |
| Primary Indication | First-line treatment of adults with ALK-positive advanced NSCLC; ALK-positive advanced NSCLC previously treated with crizotinib; adjuvant treatment of adults with completely resected stage IB (≥4 cm) to IIIA ALK-positive NSCLC |
| Manufacturer | Everest Pharmaceuticals Ltd. (Export Only) |
| Originator Reference Brand | Alecensa (alectinib) by Roche / Genentech |
| Registration Status | Export Only |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Storage Conditions | Store at room temperature (below 30°C) in a dry place, away from light and moisture. Keep out of the reach of children. |
How Alecnib 150 MG (Alectinib) Works: Next-Generation ALK Inhibition with Proven CNS Activity in ALK-Positive NSCLC
Alectinib, the active ingredient in Alecnib 150 MG, is a second-generation, highly selective, orally bioavailable small-molecule inhibitor of anaplastic lymphoma kinase (ALK) a receptor tyrosine kinase that functions as a potent oncogenic driver in non-small cell lung cancer (NSCLC) when aberrantly activated through chromosomal rearrangement. The EML4-ALK fusion gene the most common ALK rearrangement, arising from an inversion on chromosome 2p produces a constitutively active ALK fusion oncoprotein that continuously stimulates the downstream RAS/ERK, PI3K/AKT, and JAK/STAT3 intracellular signalling cascades sustaining malignant tumour cell survival, proliferation, invasion, and metastasis. An ALK tyrosine kinase inhibitor (ALK TKI) is a class of targeted oncology drugs engineered to block ALK kinase activity by competitively occupying the ATP-binding site of the ALK kinase domain, thereby interrupting the constitutive oncogenic signalling that drives ALK-positive NSCLC progression.
Alectinib achieves greater than 10-fold more potent ALK kinase inhibition compared with the first-generation ALK inhibitor crizotinib and retains full inhibitory activity against the majority of crizotinib-resistant ALK secondary point mutations including L1196M (the so-called “gatekeeper” mutation), G1269A, C1156Y, F1174L, and I1171T that represent the primary acquired resistance mechanisms limiting the durability of first-line crizotinib-based ALK inhibition.
The most clinically distinctive pharmacological feature of alectinib is its high degree of CNS penetration. CNS metastases represent the most common and most clinically devastating site of disease progression in ALK-positive NSCLC affecting up to 46% of patients within the first two years of first-generation crizotinib therapy due to crizotinib’s poor blood-brain barrier (BBB) penetration. Alectinib achieves cerebrospinal fluid (CSF) concentrations approximating estimated free plasma concentrations, a pharmacokinetic property that enables effective intracranial disease suppression. This CNS pharmacokinetic advantage translates directly into measurable clinical outcomes: in the ALEX Phase III trial, alectinib reduced the risk of CNS progression or death by 84% versus crizotinib (HR 0.16; 95% CI 0.10–0.28; p<0.0001) one of the largest CNS protection effects ever demonstrated in any randomised Phase III lung cancer trial. Oncologists sourcing ALK-directed therapies for their patients can review the complete range of lung cancer medicines available at Mediaid Pharmacy for companion and supportive care agents.
In the global, randomised ALEX Phase III trial the first head-to-head comparison of a second-generation ALK TKI against crizotinib as first-line therapy in 303 patients with advanced ALK-positive NSCLC alectinib at 600 mg twice daily (four 150 mg tablets twice daily, administered with food) delivered a final median overall survival of 81.1 months nearly seven years versus 54.2 months with crizotinib (HR 0.78; 95% CI 0.56–1.08; data cutoff April 2025). The 5-year overall survival rate was 62.5% with alectinib versus 45.5% with crizotinib, and the median duration of response in confirmed responders was 42.3 months versus 11.1 months with crizotinib (HR 0.41; 95% CI 0.30–0.56) across systemic and intracranial disease compartments simultaneously. These long-term data confirm alectinib as the current standard of care for previously untreated ALK-positive advanced NSCLC across all major international guideline bodies including NCCN, ESMO, and ASCO.
Approved Indications of Alectinib (Reference Label for Alecnib 150 MG (Alectinib))
Alectinib, the active ingredient in Alecnib 150 MG, is approved internationally across three distinct ALK-positive NSCLC treatment settings spanning the full disease continuum from resected early-stage disease through first-line advanced NSCLC to post-crizotinib relapsed disease. Prescribers should confirm the exact locally approved indications on the Alecnib product label and the applicable regulatory reference before initiating therapy. ALK-positive NSCLC status must be confirmed by an approved diagnostic assay before alectinib is initiated in any setting.
|
First-Line Advanced ALK-Positive NSCLC and Crizotinib-Pretreated Advanced ALK-Positive NSCLC Alectinib is indicated as first-line therapy for adults with ALK-positive advanced (stage IIIB/IV) NSCLC, and as second-line therapy following crizotinib failure. The ALEX Phase III trial (n=303, treatment-naïve ALK+ advanced NSCLC) delivered a final median OS of 81.1 months versus 54.2 months with crizotinib, a final median PFS of 34.8 versus 10.9 months, and a 5-year OS rate of 62.5% versus 45.5%. The complementary ALESIA Phase III trial in Asian patients (n=187) confirmed consistent efficacy with a 5-year OS rate of 66.4% (alectinib) versus 56.1% (crizotinib), confirming alectinib’s standard-of-care status across diverse patient populations and global geographies. |
Adjuvant Treatment Completely Resected Stage IB (≥4 cm) to IIIA ALK-Positive NSCLC (FDA-Approved April 2024) Alectinib was approved by the FDA in April 2024 as the first adjuvant targeted therapy for resected ALK-positive NSCLC, supported by the Phase III ALINA trial (n=257). Adjuvant alectinib reduced the risk of disease recurrence or death by 76% versus platinum-based chemotherapy (HR 0.24; 95% CI 0.13–0.43; p<0.0001). CNS disease-free survival was also significantly improved (HR 0.22; 95% CI 0.08–0.58) a 4-year CNS DFS rate of 90.4% versus 76.1% with chemotherapy establishing alectinib as the first adjuvant ALK TKI to simultaneously address systemic and CNS recurrence risk in early-stage surgically resected ALK-positive NSCLC. |
Key Clinical Benefits of Alecnib 150 MG (Alectinib)
|
Nearly 7-Year Median Overall Survival in First-Line Advanced ALK-Positive NSCLC The Longest OS Reported for Any First-Line ALK TKI vs Crizotinib Final ALEX trial data (data cutoff April 2025) confirmed alectinib 600 mg twice daily delivered a median OS of 81.1 months (approximately 6.75 years) versus 54.2 months with crizotinib a clinically and statistically meaningful 26.9-month median OS advantage alongside a median DOR of 42.3 versus 11.1 months (HR 0.41) and a 5-year OS rate of 62.5% versus 45.5%, demonstrating that the survival benefit of alectinib deepens and persists over multi-year follow-up in the first-line advanced ALK-positive NSCLC setting. |
84% Reduction in CNS Progression Risk in Advanced Disease + 78% Reduction in CNS Recurrence in the Adjuvant Setting Alectinib’s superior CNS penetration delivers measurable intracranial disease control across both the advanced metastatic and early-stage settings. In ALEX, alectinib reduced CNS progression or death by 84% versus crizotinib (HR 0.16; 95% CI 0.10–0.28; p<0.0001). In ALINA, adjuvant alectinib reduced CNS recurrence events by 78% versus platinum chemotherapy (HR 0.22; 95% CI 0.08–0.58), achieving a 4-year CNS DFS rate of 90.4% versus 76.1% demonstrating that alectinib’s intracranial activity extends from prevention of CNS metastasis in early-stage resected patients through active CNS disease suppression in the metastatic setting. |
Activity Retained Across Crizotinib-Resistant ALK Mutations Broad Second-Line Efficacy in ALK TKI-Pretreated NSCLC Alectinib retains potent inhibitory activity against the majority of secondary ALK resistance mutations that drive acquired crizotinib resistance including the L1196M gatekeeper mutation, G1269A, C1156Y, F1174L, and I1171T. In the Phase III ALUR trial of alectinib in crizotinib-pretreated advanced ALK-positive NSCLC (n=107), alectinib significantly extended PFS versus chemotherapy and demonstrated meaningful intracranial responses in patients with established CNS metastases at baseline confirming durable second-line activity in a patient population that has exhausted first-generation ALK TKI options. |
Dosage and Administration of Alecnib 150 MG (Alectinib)
Administration Rule Must Be Taken With Food: Alectinib must be taken with food to ensure consistent oral bioavailability. Swallow Alecnib 150 MG tablets whole with water. Do not crush, split, or chew the tablets before swallowing. The full approved dose of 600 mg twice daily is achieved by taking four 150 mg tablets (four Alecnib 150 MG tablets) twice daily consuming four tablets with the morning meal and four tablets with the evening meal, approximately 12 hours apart. Maintaining consistent meal timing supports stable plasma drug concentrations throughout the continuous dosing schedule. If a dose is missed and less than 6 hours have passed since the scheduled dose time, take the missed dose immediately with food and resume the regular schedule; if more than 6 hours have elapsed, skip the missed dose and take the next scheduled dose at the usual time. Do not take a double dose to compensate for a missed one.
Advanced ALK-Positive NSCLC (First-Line and Post-Crizotinib) Standard Dose (600 mg Twice Daily, Continuous Schedule): The reference label specifies 600 mg twice daily (BID) on a continuous once-daily schedule for all approved advanced NSCLC indications including treatment-naïve first-line ALK-positive advanced NSCLC and ALK-positive advanced NSCLC previously treated with crizotinib. Four Alecnib 150 MG tablets taken twice daily with food approximately 12 hours apart delivers the 1,200 mg total daily alectinib dose validated in the ALEX, J-ALEX, ALESIA, and ALUR Phase II/III clinical trial programmes. Alectinib is administered on a continuous schedule without planned treatment breaks until disease progression or unacceptable toxicity; there is no loading dose regimen or planned dose escalation from the approved starting dose.
Adjuvant Setting (Resected Stage IB to IIIA ALK-Positive NSCLC) 600 mg Twice Daily for Two Years: In the adjuvant post-resection setting, the reference label specifies 600 mg twice daily for a planned treatment duration of two years, consistent with the ALINA Phase III trial design in which alectinib administered for two years reduced the risk of disease recurrence or death by 76% versus platinum-based chemotherapy (HR 0.24; p<0.0001). Adjuvant alectinib should commence within 12 weeks of complete tumour resection and following adequate post-surgical recovery. Adjuvant treatment is discontinued at confirmed disease recurrence, unacceptable toxicity, or at the planned end of the two-year treatment period whichever occurs first.
Dose Reduction Schedule for Adverse Event Management: If alectinib-related adverse events including Grade 3 or 4 hepatotoxicity, ILD/pneumonitis, symptomatic bradycardia, Grade 3 or 4 CPK elevation, or significant haematological toxicity require dose modification, the reference label specifies a stepwise reduction: first to 450 mg twice daily (three Alecnib 150 MG tablets twice daily), then to 300 mg twice daily (two Alecnib 150 MG tablets twice daily) if further reduction remains necessary. Permanent discontinuation of alectinib is required for Grade 4 ILD/pneumonitis or recurrent Grade 3 or higher toxicity that fails to recover to Grade 1 or baseline following two dose reduction steps. All dose modification decisions must be directed by the treating oncologist using NCI Common Terminology Criteria for Adverse Events (CTCAE) grading guidance.
Dose Adjustment for CYP3A4 Inhibitors and Inducers: Alectinib is primarily metabolised by CYP3A4 to its active metabolite M4 which has comparable ALK inhibitory activity to the parent compound. Co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir-based antiretrovirals) significantly increases alectinib and M4 plasma exposure and requires close adverse event monitoring with dose guidance from the treating oncologist. Strong CYP3A4 inducers including rifampicin, carbamazepine, phenytoin, and St John’s Wort substantially reduce alectinib plasma concentrations, potentially rendering treatment sub-therapeutic, and should be avoided throughout the alectinib treatment course where clinically feasible. The prescribing oncologist should review all concomitant medications before and during alectinib therapy.
Clinical Monitoring Requirements During Alecnib 150 MG (Alectinib) Treatment
Liver function monitoring is the primary biochemical safety requirement for all patients receiving alectinib. The reference label mandates liver function tests (ALT, AST, and total bilirubin) every 2 weeks during the first 3 months of treatment, then monthly and as clinically indicated for the remainder of the treatment course. ALT or AST elevation greater than 5 times the upper limit of normal (ULN) with concurrent total bilirubin ≤2× ULN or total bilirubin greater than 3× ULN each require alectinib treatment interruption until values recover to Grade 1 or baseline, with permanent discontinuation required for recurrent Grade 3 hepatotoxicity or any Grade 4 hepatotoxicity event. Patients with pre-existing hepatic impairment require individualised assessment before and during alectinib therapy; the reference label provides specific guidance for moderate and severe hepatic impairment that prescribing oncologists should apply before initiating treatment.
Cardiac monitoring for symptomatic bradycardia is required throughout the entire alectinib treatment period. A resting heart rate below 60 beats per minute (bpm) symptomatic bradycardia has been reported in approximately 11% of alectinib-treated patients across Phase III clinical trial programmes. Baseline resting heart rate and blood pressure must be assessed before initiating Alecnib 150 MG, and heart rate should be evaluated at each scheduled oncology review, with particular attention to any report of new-onset dizziness, syncope, palpitations, or exercise intolerance. Grade 2 or 3 symptomatic bradycardia requires treatment interruption and a careful review of all concomitant chronotropic medications including beta-adrenergic blocking agents, non-dihydropyridine calcium channel blockers, ivabradine, and antiarrhythmic drugs that may potentiate alectinib-associated heart rate reduction.
Pulmonary surveillance for interstitial lung disease (ILD) and pneumonitis must be incorporated into every scheduled clinical review any new or worsening dyspnoea, dry cough, fever, or unexplained radiological infiltrates warrant immediate alectinib interruption, chest imaging, and clinical investigation before treatment can be resumed. CPK monitoring should be performed monthly for the first 3 months and as clinically indicated thereafter; Grade 3 or 4 CPK elevation (greater than 5× ULN) often accompanied by severe myalgia or significant musculoskeletal pain requires treatment interruption until recovery to Grade 1 or baseline. Photosensitivity risk counselling must be provided at treatment initiation patients should be instructed to limit direct sun exposure, wear protective clothing when outdoors, and apply broad-spectrum sunscreen to all sun-exposed skin areas throughout the alectinib treatment period.
Drug Interactions and Important Safety Information for Alecnib 150 MG (Alectinib)
The most clinically significant drug interactions for alectinib centre on its role as a CYP3A4 substrate and as an inhibitor of P-glycoprotein (P-gp) and BCRP efflux transporters. Alectinib is metabolised primarily by CYP3A4 to its active metabolite M4 (which retains equivalent ALK inhibitory activity to the parent compound); strong CYP3A4 inhibitors including systemic azole antifungals (ketoconazole, itraconazole, voriconazole), clarithromycin, and ritonavir-based antiretroviral regimens can significantly increase alectinib and M4 plasma exposure and elevate systemic adverse event risk.
Close monitoring for hepatotoxicity, bradycardia, CPK elevation, and ILD is required during any unavoidable co-administration, and the treating oncologist should guide dose management decisions throughout the co-administration period. Strong CYP3A4 inducers rifampicin, carbamazepine, phenytoin, primidone, and St John’s Wort substantially reduce alectinib and M4 plasma concentrations, potentially compromising the continuous ALK inhibition required for durable disease suppression; the reference label advises avoiding these combinations where clinically feasible throughout the entire alectinib treatment course.
Because alectinib and M4 are inhibitors of both P-glycoprotein (P-gp) and BCRP efflux transporters, co-administration with P-gp or BCRP substrates that carry narrow therapeutic indices including digoxin, dabigatran, rosuvastatin, and methotrexate may increase the plasma concentrations and associated toxicity risk of these co-administered agents. Clinical monitoring and, where indicated, dose adjustment of the P-gp or BCRP substrate under the supervision of the treating oncologist is required in these combinations. Concomitant chronotropic agents including beta-adrenergic blocking drugs, non-dihydropyridine calcium channel blockers (diltiazem, verapamil), ivabradine, digoxin, and antiarrhythmic agents can potentiate the bradycardic effect of alectinib; the combination requires baseline and ongoing cardiac monitoring with documented heart rate assessments at each clinical review.
All patients beginning Alecnib 150 MG treatment must provide a complete medication history including all prescription drugs, over-the-counter preparations, herbal supplements, and gastric acid-reducing agents so that the treating oncologist can assess and manage potential drug interactions before and throughout the alectinib treatment course. For sourcing of additional targeted, cytotoxic, or immunotherapy agents required alongside alectinib in comprehensive lung cancer treatment regimens, the full range of oncology medicines available for worldwide dispatch is listed on the Mediaid Pharmacy website.
Side Effects and Precautions of Alecnib 150 MG (Alectinib)
|
Common Side Effects Fatigue and asthenia (approximately 41% of patients; the most frequently reported adverse event in alectinib Phase III programmes predominantly Grade 1–2 and often manageable without dose modification) Constipation (~35%; the most common gastrointestinal adverse event; dietary fibre supplementation and prophylactic laxative strategies are routinely employed in clinical practice) Myalgia (~29%) and arthralgia musculoskeletal pain that may co-occur with CPK elevation; dose interruption may be required for Grade 3 or higher events Peripheral oedema (~28%; typically Grade 1–2 oedema affecting the lower limbs, face, or periorbital region) Nausea (~22%) and vomiting; taking Alecnib tablets with food reduces gastrointestinal tolerability events in most patients Elevated liver transaminases ALT and/or AST requiring scheduled liver function monitoring every 2 weeks for the first 3 months, then monthly Photosensitivity reactions (sun-exposed skin rash, erythema, or burning); sun avoidance and broad-spectrum sunscreen use throughout treatment are mandatory Symptomatic bradycardia (approximately 11%; typically manageable with dose interruption and concomitant chronotropic medication review) Weight gain and increased appetite reported during continuous long-term alectinib therapy in Phase III trial programmes |
Serious Warnings and Precautions Interstitial lung disease (ILD) and pneumonitis: serious ILD and pneumonitis including fatal cases have been reported in alectinib-treated patients. Any new or progressively worsening dyspnoea, cough, fever, or radiological pulmonary infiltrates during Alecnib 150 MG therapy require immediate treatment interruption and urgent clinical investigation. Permanent discontinuation is mandatory for Grade 3 or 4 ILD/pneumonitis. Hepatotoxicity: Grade 3 or 4 ALT/AST elevations have been reported in alectinib Phase III clinical trials. Liver function tests (ALT, AST, and total bilirubin) are required every 2 weeks for the first 3 months of treatment, then monthly and as clinically indicated thereafter. Permanent discontinuation is required for recurrent Grade 3 or any Grade 4 hepatotoxicity. Severe CPK elevation and myopathy: Grade 3 or 4 CPK elevation (greater than 5× ULN) accompanied by significant myalgia or musculoskeletal pain requires treatment interruption until recovery to Grade 1 or baseline before alectinib may be restarted at the same or reduced dose per the oncologist’s clinical assessment. Symptomatic bradycardia requiring management: Grade 3 or life-threatening symptomatic bradycardia requires alectinib dose interruption and a comprehensive review of all concomitant chronotropic medications. If no contributing concomitant medication can be adjusted and bradycardia does not resolve to Grade 1, permanent alectinib discontinuation should be considered. Embryo-fetal toxicity: alectinib can cause fetal harm. Females of reproductive potential must use effective contraception during treatment and for at least 1 week after the final dose. Males with female partners of reproductive potential must use contraception during treatment and for at least 3 months after the last dose. Breastfeeding is contraindicated during treatment and for at least 1 week after the final alectinib dose. |
Who Should Use Alecnib 150 MG (Alectinib)?
Alecnib 150 MG (Alectinib) is the unit-dose tablet formulation of alectinib for adults with ALK-positive advanced NSCLC in the first-line setting, for adults with ALK-positive advanced NSCLC previously treated with crizotinib, and for adults who have undergone complete surgical resection of stage IB (tumours ≥4 cm) to IIIA ALK-positive NSCLC who are eligible for adjuvant targeted therapy. All three approved indications require prior documentation of ALK-positive NSCLC status confirmed by a validated diagnostic assay the VENTANA ALK (D5F3) CDx assay or an FDA-approved next-generation sequencing (NGS) panel before Alecnib 150 MG is initiated.
Oncologists managing ALK-positive NSCLC assess baseline liver function (ALT, AST, total bilirubin), resting heart rate and blood pressure, pulmonary function and imaging, CPK levels, photosensitivity history, and a full concomitant medication review covering CYP3A4 inhibitors and inducers, P-gp substrates with narrow therapeutic windows, and all chronotropic agents before prescribing Alecnib 150 MG. Patients with moderate or severe hepatic impairment, active uncontrolled ILD, established symptomatic bradycardia on maximally managed chronotropic medications, or those who are pregnant, breastfeeding, or of reproductive potential without adequate contraceptive coverage require individualised assessment and risk counselling before treatment begins.
For patients who require additional targeted agents including osimertinib for concurrent EGFR-mutant disease, immunotherapy combinations, or supportive agents or who need antinausea, antiemetic, or laxative supportive medicines alongside alectinib, Mediaid Pharmacy’s oncology specialty medicines range provides a comprehensive selection of approved agents available for global delivery.
Global Supplier: Mediaid Pharmacy Worldwide Shipping for Alecnib 150 MG (Alectinib)
Mediaid Pharmacy is a Dhaka-based supplier of oncology and specialty medicines operating with worldwide shipping capability. Alecnib 150 MG (Alectinib) manufactured by Everest Pharmaceuticals Ltd. for export is available in a 56-tablet pack, and all orders are supported by pricing quotations, stock confirmation, export documentation, and end-to-end international delivery tracking. Hospitals, specialist thoracic oncology departments, medical oncology clinics, international distributors, and individual patients can contact the Mediaid Pharmacy team through WhatsApp, phone, or WeChat for all enquiries regarding Alecnib 150 MG Alectinib stock availability, pricing, and international shipping timelines to their country. Buyers sourcing multiple lung cancer, ALK-targeted, or oncology medicines in a single consolidated shipment can browse the complete lung cancer medicines collection at Mediaid Pharmacy before submitting a multi-product quotation request.
Why Choose Alecnib 150 MG (Alectinib) from Mediaid Pharmacy?
Alecnib 150 MG (Alectinib) provides thoracic oncology and medical oncology teams with a 150 mg alectinib tablet in a 56’s export pack the unit-dose strength that delivers the globally validated 600 mg twice-daily alectinib regimen underpinning the ALEX trial (final median OS 81.1 vs 54.2 months with crizotinib; 5-year OS 62.5% vs 45.5%; final median PFS 34.8 vs 10.9 months; CNS progression risk reduced by 84%; HR 0.16), the ALINA adjuvant trial (DFS HR 0.24; p<0.0001; 76% recurrence risk reduction; CNS DFS HR 0.22; 4-year CNS DFS 90.4% vs 76.1% with chemotherapy), the ALESIA Phase III trial in Asian patients (5-year OS 66.4% vs 56.1%), and the ALUR Phase III trial in crizotinib-pretreated patients.
With more than 92,000 patients treated with alectinib in clinical practice globally as of 2023 and a long-term safety profile consistent across multi-year follow-up in every registrational study, alectinib is among the most extensively validated targeted therapies in thoracic oncology. Manufactured by Everest Pharmaceuticals Ltd. as an export product, Alecnib 150 MG is an accessible oncology-grade tablet formulation designed for international supply suitable for hospitals, oncology clinics, and patients requiring reliable, continuous access to alectinib 600 mg twice-daily ALK inhibition therapy.
Mediaid Pharmacy supplies Alecnib 150 MG in 56’s export packs with full product documentation, regulatory export support, and worldwide shipping from Dhaka. Every order is initiated through a prescription-verified enquiry to maintain appropriate clinical governance of supply. To source additional ALK-positive NSCLC therapies, complementary oncology agents, or to request a personalised multi-product quotation, visit the Mediaid Pharmacy oncology medicines section and contact the team directly.
Frequently Asked Questions About Alecnib 150 MG (Alectinib)
What is Alecnib 150 MG (Alectinib) used for?
Alecnib 150 MG (Alectinib) is an oral, second-generation ALK tyrosine kinase inhibitor (TKI) manufactured by Everest Pharmaceuticals Ltd. for export, used to treat anaplastic lymphoma kinase-positive (ALK-positive) non-small cell lung cancer (NSCLC) in adults. It is indicated as first-line therapy for adults with ALK-positive advanced NSCLC, as second-line therapy for adults with ALK-positive advanced NSCLC previously treated with crizotinib, and since April 2024 as adjuvant therapy for adults who have undergone complete tumour resection of stage IB (tumours ≥4 cm) to IIIA ALK-positive NSCLC. Alectinib works by potently inhibiting the ALK kinase domain blocking the downstream RAS/ERK, PI3K/AKT, and JAK/STAT3 signalling cascades that sustain malignant cell survival and proliferation in ALK-rearranged NSCLC tumours while demonstrating exceptional CNS penetration that enables simultaneous systemic and intracranial disease control.
What is the generic name of Alecnib 150 MG?
The generic name of Alecnib 150 MG is alectinib INN. Alecnib 150 MG is a tablet formulation available in a 56’s pack (56 tablets per pack), manufactured by Everest Pharmaceuticals Ltd. for export. The originator reference brand for alectinib is Alecensa, developed and commercialised by Roche and Genentech, which is approved in the United States, the European Union, Japan, and other major international markets for first-line and crizotinib-pretreated ALK-positive advanced NSCLC and for adjuvant treatment of completely resected ALK-positive NSCLC.
How many Alecnib 150 MG tablets should I take per day?
The reference label recommends 600 mg twice daily (BID) for all approved alectinib indications. This dose is achieved by taking four Alecnib 150 MG tablets (4 × 150 mg = 600 mg) in the morning with food and four Alecnib 150 MG tablets (4 × 150 mg = 600 mg) in the evening with food a total of eight tablets (1,200 mg) per day. In the adjuvant post-resection setting, this dose is maintained for two years. The dose must always be determined and supervised by the treating oncologist; never adjust or alter your dose without your prescribing specialist’s explicit direction.
What pack size does Alecnib (Alectinib) come in and how long does one pack last?
Alecnib 150 MG (Alectinib) is available as a 56-tablet export pack (56 tablets per pack), manufactured by Everest Pharmaceuticals Ltd. At the standard dose of 600 mg twice daily which requires eight 150 mg tablets per day a single 56-tablet pack provides a seven-day supply. Hospitals, oncology clinics, and patients planning continuous alectinib therapy should calculate multi-pack requirements accordingly and contact Mediaid Pharmacy for current stock availability, pricing, and worldwide shipping details.
What are the side effects of Alecnib 150 MG (Alectinib)?
Common side effects of alectinib 150 mg include fatigue (~41%), constipation (~35%), myalgia (~29%), peripheral oedema (~28%), nausea (~22%), elevated liver transaminases (ALT/AST requiring scheduled monitoring), photosensitivity reactions, symptomatic bradycardia (~11%), CPK elevation with associated musculoskeletal pain, and weight gain. Serious adverse effects less frequent but requiring immediate clinical action include ILD/pneumonitis (including fatal cases), Grade 3 or 4 hepatotoxicity, Grade 3 or 4 CPK elevation, and embryo-fetal toxicity. Liver function tests (every 2 weeks for the first 3 months, then monthly), heart rate monitoring, CPK assessment (monthly for the first 3 months), and photosensitivity precautions are mandatory throughout treatment. Consult your prescribing oncologist regarding your individual risk profile and monitoring schedule before and during alectinib therapy.
What does the ALEX trial tell us about alectinib’s long-term survival benefit versus crizotinib?
The ALEX Phase III trial (NCT02075840) is the registrational global randomised trial that established alectinib as the standard of care for first-line ALK-positive advanced NSCLC. In 303 previously untreated patients with advanced ALK-positive NSCLC randomised 1:1 to alectinib 600 mg BID or crizotinib 250 mg BID, the final ALEX analysis (data cutoff April 2025) confirmed a median overall survival of 81.1 months (approximately 6.75 years) with alectinib versus 54.2 months with crizotinib (HR 0.78; 95% CI 0.56–1.08), a median progression-free survival of 34.8 versus 10.9 months, a 5-year OS rate of 62.5% versus 45.5%, and a median duration of response of 42.3 versus 11.1 months (HR 0.41). ALEX also confirmed an 84% reduction in CNS progression risk with alectinib (HR 0.16; 95% CI 0.10–0.28; p<0.0001), confirming that alectinib delivers simultaneous and durable systemic and intracranial disease control the primary clinical objective in a tumour where CNS metastasis represents both a prognostic and quality-of-life determinant.
Is Alecnib 150 MG (Alectinib) approved for use after surgery to prevent lung cancer recurrence?
Yes. The US FDA approved alectinib in April 2024 as adjuvant treatment for adults with completely resected ALK-positive NSCLC stage IB (tumours ≥4 cm) to IIIA based on the Phase III ALINA trial results. In ALINA (n=257), adjuvant alectinib 600 mg twice daily administered for two years reduced the risk of disease recurrence or death by 76% versus platinum-based chemotherapy (HR 0.24; 95% CI 0.13–0.43; p<0.0001). CNS disease-free survival was also significantly improved (HR 0.22; 95% CI 0.08–0.58), with a 4-year CNS DFS rate of 90.4% with alectinib versus 76.1% with chemotherapy positioning adjuvant alectinib as a category-defining breakthrough for preventing both systemic and CNS recurrence following surgical resection of ALK-positive NSCLC. The adjuvant indication requires prior confirmation of ALK-positive NSCLC status by an approved diagnostic test before alectinib is initiated.
Is Alecnib 150 MG (Alectinib) safe during pregnancy or while breastfeeding?
No. Alectinib can cause fetal harm based on its pharmacological mechanism of action and non-clinical reproductive toxicity studies. Females of reproductive potential must use effective non-hormonal or hormonal contraception during treatment with Alecnib 150 MG and for at least 1 week after the final dose. Males with female partners of reproductive potential must use effective contraception during alectinib treatment and for at least 3 months after the last dose. Breastfeeding is not recommended during treatment with Alecnib 150 MG and for at least 1 week after the final dose. Patients who are pregnant, planning a pregnancy, or currently breastfeeding must discuss individual risk counselling with their prescribing oncologist before Alecnib 150 MG is initiated.
Can I order Alecnib 150 MG (Alectinib) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies Alecnib 150 MG (Alectinib) manufactured by Everest Pharmaceuticals Ltd. for export to patients and healthcare providers globally. Contact Mediaid Pharmacy via WhatsApp, phone, or WeChat at +8801773428128, or email info@mediaidpharmacy.com for current stock availability, pricing, export documentation support, and international delivery details for your country.
Order Alecnib 150 MG (Alectinib) with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com
Reviews
There are no reviews yet.